the move by johnson  johnson has been widely expected and the firm will pay 76 for each guidant share 6 more than wednesdays closing pricepharmaceutical giant johnson  johnson has agreed to buy medical technology firm guidant for 254bn Â£13bnanalysts said that the deal is aimed at offsetting johnson  johnsons reliance on a slowing drug businessa number of johnson  johnsons products are facing patent expirations while the company is also battling fierce competition from generic products
